Long-Read Sequencing Enhances Pharmacogenomic Profiling by Resolving Complex Haplotypes, Novel Star Alleles, and...

Area of Science:

• Genomics
• Pharmacogenomics
• Molecular Biology

Background:

• Pharmacogenomics personalizes drug therapy using genetic biomarkers.
• Traditional short-read sequencing struggles with complex pharmacogene structures, leading to inaccurate phenotype predictions.

Purpose of the Study:

• To evaluate long-read sequencing technologies (Oxford Nanopore, PacBio) for resolving pharmacogene complexity.
• To compare long-read sequencing with short-read sequencing for diplotype and drug response phenotype analysis.

Main Methods:

• Analyzed 20 pharmacogenes in 1,000 Genomes Project and Genomics England cohorts using long-read and short-read sequencing.
• Assessed phasing accuracy, variant detection, and genotype/phenotype concordance.
• Identified novel alleles and resolved complex structural variants.

Main Results:

• Long reads achieved high phasing accuracy (>96.5%) and variant detection (precision, recall, F1 >0.92).
• Genotype and phenotype concordance exceeded 99%, with long reads contributing fewer discordant cases.
• Discovered 19 novel star alleles, 106 suballeles, and resolved 13 ambiguous CYP2D6 variants; identified a UGT1A1*80+*28 homozygous genotype.

Conclusions:

• Long-read sequencing significantly improves phasing and resolution of complex pharmacogenomic regions.
• This technology enables more precise pharmacogenomic profiling, enhancing drug safety and efficacy.
• Long-read sequencing is poised to become the preferred method in clinical pharmacogenomics.